# A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

> **NCT00641082** · PHASE4 · COMPLETED · sponsor: **Bukwang Pharmaceutical** · enrollment: 43 (actual)

## Conditions studied

- HBeAg(-) Chronic Hepatitis B With Compensated Liver Function

## Interventions

- **DRUG:** Clevudine
- **DRUG:** Adefovir dipivoxil

## Key facts

- **NCT ID:** NCT00641082
- **Lead sponsor:** Bukwang Pharmaceutical
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2008-02
- **Primary completion:** 2012-03
- **Final completion:** —
- **Target enrollment:** 43 (ACTUAL)
- **Last updated:** 2012-04-25


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00641082

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00641082, "A Double-Blind Randomized Clinical Trial Comparing the Safety and Antiviral Activity of 48-week Clevudine and Adefovir Dipivoxil in HBeAg(-) Chronic Hepatitis B With Compensated Liver Function". Retrieved via AI Analytics 2026-06-24 from https://api.ai-analytics.org/clinical/NCT00641082. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*